These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
709 related articles for article (PubMed ID: 9823984)
1. Expression of c-erbB3 protein in primary breast carcinomas. Naidu R; Yadav M; Nair S; Kutty MK Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984 [TBL] [Abstract][Full Text] [Related]
2. Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction. Naidu R; Wahab NA; Yadav M; Kutty MK; Nair S Int J Mol Med; 2001 Aug; 8(2):193-8. PubMed ID: 11445874 [TBL] [Abstract][Full Text] [Related]
3. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Naidu R; Wahab NA; Yadav MM; Kutty MK Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of p53 expression in primary breast carcinomas. Naidu R; Yadav M; Nair S; Kutty KK Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057 [TBL] [Abstract][Full Text] [Related]
5. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Naidu R; Wahab NA; Yadav M; Kutty MK Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932 [TBL] [Abstract][Full Text] [Related]
6. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662 [TBL] [Abstract][Full Text] [Related]
7. [Her-2 amplification and p185 expression in invasive breast cancer cells in women]. Titi S Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393 [TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions. Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376 [TBL] [Abstract][Full Text] [Related]
9. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825 [TBL] [Abstract][Full Text] [Related]
11. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. Somerville JE; Clarke LA; Biggart JD J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789 [TBL] [Abstract][Full Text] [Related]
12. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Rehman S; Crow J; Revell PA Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981 [TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression. Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637 [TBL] [Abstract][Full Text] [Related]
15. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161 [TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation in ductal carcinoma in situ of the male breast. Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768 [TBL] [Abstract][Full Text] [Related]
18. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study. Umekita Y; Takasaki T; Yoshida H Virchows Arch; 1994; 424(5):491-4. PubMed ID: 7913368 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma. Simpson JF; O'Malley F; Dupont WD; Page DL Cancer; 1994 May; 73(9):2352-8. PubMed ID: 7513249 [TBL] [Abstract][Full Text] [Related]
20. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients. Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]